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Background
Chronic hepatitis C (HCV) infects approximately 170 million people and causes more than 350 000 deaths every year. Information regarding pathogenetic mechanism of acute hepatitis C infection is limited. Following innate immune activation, cellular immunity, including natural killer (NK) cell activation and antigen-specific CD8 cell proliferation occurs. CD8+ T lymphocytes directly kill infected cells via direct cell-cell contact, and release antiviral cytokines (e.g. IFN, TNF)
Methods
Eleven HCV-treatment naive HCV infected patients were treated with weight-based ribavirin daily in addition to either weekly pegIFN alfa-2b at 1.5 ug/kg, weekly pegIFN alfa-2a, or albinterferon alfa-2b at 900mcg every 2 weeks. All patients gave written informed consent approved by the Institutional Review Board prior to enrollment in the studies. Intensive serum monitoring was completed at study visits day 0 (pretreatment), weeks 4, 6 and 12.
Results
In this present study, we aimed to investigate the relationship between IFN treatment response, HCV viral load and sApo 2L levels. Eleven HCV-treatment naive HCV infected patients were treated with pegIFN alfa-2a. Intensive serum circulating Apo 2L levels were monitered at study visits day 0 (pretreatment), weeks 4, 6 and 12.HCV-RNA and sApo 2L levels decreased gradually with PegIF-α 2 treatment and the differences were significant between day 0 and 4 th week (p=0.001, p<0.005 and p=0.01, p<0.005 respectively); between day
